Jeffrey Lewis Featured in Endpoints News on Supreme Court Skinny Label Case

The U.S. Supreme Court will review the Hikma-Amarin dispute involving "skinny labels," which allow generic drugmakers to enter markets sooner by excluding patented indications. The Court selected this case over an earlier GSK-Teva skinny label litigation due to its cleaner factual record. Foley Hoag partner Jeffrey Lewis noted the Court chose a more straightforward case to address this pharmaceutical patent issue definitively.